Major pharmaceutical companies are ramping up their acquisition strategies in 2026, driven by patent expiries and a surge in biotech deal values, as they seek to secure future growth and fill pipeline gaps amid market wobbles.
Big pharmaceutical companies are entering 2026 with a renewed appetite for acquisitions as the industry braces for a wave of patent expiries that threaten long-standing revenue streams. According to reporting by Investing.com, first-quarter biotech deal value reached $84bn, almost double the $44.4bn recorded a year earlier and the strongest opening to a year since 2019. Analysts cited by the outlet said the combination of large cash balances, relatively modest biotech valuations and a steady run of newly approved therapies is pushing buyers back into the market.
The strategic logic is straightforward: drugmakers are trying to fill pipeline gaps before the patent cliff bites more deeply. Pharmaceutical Commerce said the looming loss of exclusivity could put as much as $300bn in annual sales at risk by 2032, prompting companies to focus on first-in-class and best-in-class assets that fit neatly into existing franchises. McKinsey has similarly argued that biopharma remains a growth-led deal market, with 76% of transactions between 2020 and 2025 aimed at expansion rather than cost cutting, as executives look for innovation to replace ageing blockbusters.
That pressure is already shaping boardroom thinking across the sector. Pharmaceutical Technology reported that Bristol Myers Squibb is leaning on its internal pipeline to offset the eventual decline of Opdivo and Eliquis, with chief executive Christopher Boerner telling investors at the J.P. Morgan Healthcare conference that a series of upcoming readouts could support earnings through the end of the decade. The broader message from management teams is clear: companies with enough confidence in their own research may delay acquisitions, but those with thinner pipelines are likely to keep shopping.
The M&A rush is also taking place against a market backdrop that still favours buyers. McKinsey said strategic investors’ cash reserves rose 10% between 2021 and 2024, while private equity holding periods lengthened, suggesting more assets may come to market. If the current pace continues, Investing.com reported that 2026 biopharma deal value could top $250bn, which would make it the second-biggest year on record after 2019. For now, the sector’s deal appetite appears to be driven less by optimism than by urgency.
Source Reference Map
Inspired by headline at: [1]
Sources by paragraph:
Source: Noah Wire Services
Noah Fact Check Pro
The draft above was created using the information available at the time the story first
emerged. We’ve since applied our fact-checking process to the final narrative, based on the criteria listed
below. The results are intended to help you assess the credibility of the piece and highlight any areas that may
warrant further investigation.
Freshness check
Score:
8
Notes:
The article was published on May 1, 2026, reporting on biotech M&A activity in the first quarter of 2026, with a total deal value of $84 billion, up from $44.4 billion a year earlier. ([investing.com](https://www.investing.com/news/stock-market-news/big-pharma-ma-set-for-mega-year-as-patent-expiries-drive-deal-urgency-4653562?utm_source=openai)) This aligns with recent reports from McKinsey and Deloitte, which also highlight increased M&A activity in the life sciences sector in 2026. ([mckinsey.com](https://www.mckinsey.com/capabilities/m-and-a/our-insights/life-sciences-dealmaking-gains-momentum-as-strategic-pressures-intensify?utm_source=openai)) However, the article does not provide specific details about the earliest known publication date of similar content, making it difficult to assess the originality of the narrative. Additionally, the article includes updated data but recycles older material, such as the mention of patent expiries and their impact on M&A activity, which has been a topic of discussion in previous years.
Quotes check
Score:
6
Notes:
The article includes direct quotes from analysts, investors, and a banker regarding the surge in biotech M&A activity in 2026. ([investing.com](https://www.investing.com/news/stock-market-news/big-pharma-ma-set-for-mega-year-as-patent-expiries-drive-deal-urgency-4653562?utm_source=openai)) However, these quotes cannot be independently verified, as no specific names or affiliations are provided. Without verifiable sources, the credibility of these quotes is questionable.
Source reliability
Score:
7
Notes:
The article is sourced from Reuters, a major news organisation known for its journalistic standards. ([investing.com](https://www.investing.com/news/stock-market-news/big-pharma-ma-set-for-mega-year-as-patent-expiries-drive-deal-urgency-4653562?utm_source=openai)) However, the article does not provide specific details about the analysts, investors, or banker quoted, making it difficult to assess the reliability of these sources. Additionally, the article includes information from Investing.com, which is a financial news and data website. While Investing.com is generally considered reliable, it is not as established as Reuters.
Plausibility check
Score:
8
Notes:
The article's claims about the surge in biotech M&A activity in 2026 are plausible and align with recent industry reports. ([mckinsey.com](https://www.mckinsey.com/capabilities/m-and-a/our-insights/life-sciences-dealmaking-gains-momentum-as-strategic-pressures-intensify?utm_source=openai)) However, the article does not provide specific details about the companies involved in the reported deals, making it difficult to assess the accuracy of the claims. Additionally, the article mentions that the surge in M&A activity is driven by patent expiries, but does not provide specific examples or data to support this claim.
Overall assessment
Verdict (FAIL, OPEN, PASS): OPEN
Confidence (LOW, MEDIUM, HIGH): MEDIUM
Summary:
The article reports on a surge in biotech M&A activity in 2026, citing a total deal value of $84 billion in the first quarter, up from $44.4 billion a year earlier. ([investing.com](https://www.investing.com/news/stock-market-news/big-pharma-ma-set-for-mega-year-as-patent-expiries-drive-deal-urgency-4653562?utm_source=openai)) While this aligns with recent industry reports, the article lacks specific details about the earliest known publication date of similar content, making it difficult to assess the originality of the narrative. Additionally, the article includes quotes from analysts, investors, and a banker, but without verifiable sources, the credibility of these quotes is questionable. The article also mentions that the surge in M&A activity is driven by patent expiries but does not provide specific examples or data to support this claim. Given these concerns, the overall assessment is OPEN with medium confidence.
